Abstract
We evaluated whether V-5 Immunitor (V5), tableted immunotherapeutic preparation comprising heatinactivated HBV antigens from pooled blood of HBV- and HCV-infected donors, may produce clinical benefit through induction of oral tolerance and reduction of immune-mediated liver injury. Once daily dose of V5 was administered per os to 10 patients with chronic hepatitis B in an open label study that lasted one month. Every patient who entered the study had elevated liver enzyme levels, which at the end of study have decreased in 100% of analyzed patients. The reduction was highly significant, from 112.4 to 44.4 U/L (P=0.00009) and 118.8 to 46.1 U/L (P=0.0032), for ALT and AST respectively. In addition, half of intent-to-treat patients who were HBV surface antigen (HBsAg) positive at study entry, became negative after one month on V5 (P=0.0098). All patients, except one, reported complete recuperation from hepatitisassociated clinical symptoms present at baseline (P=0.0016). No adverse events were observed at any time. Favorable biochemical, virological and clinical responses indicate that V5 is safe and effective means for immunotherapy of chronic hepatitis B. Placebo-controlled, randomized study is required to confirm these findings.
Keywords: Hepatitis B, Liver function test, Therapeutic vaccine, Immunomodulating supplement, per os
Letters in Drug Design & Discovery
Title: Open Label Trial of Therapeutic Hepatitis B Vaccine V-5 Immunitor (V5)Delivered by Oral Route
Volume: 4 Issue: 8
Author(s): Dendev Batdelger, Dorjiin Dandii, Vichai Jirathitikal and Aldar S. Bourinbaiar
Affiliation:
Keywords: Hepatitis B, Liver function test, Therapeutic vaccine, Immunomodulating supplement, per os
Abstract: We evaluated whether V-5 Immunitor (V5), tableted immunotherapeutic preparation comprising heatinactivated HBV antigens from pooled blood of HBV- and HCV-infected donors, may produce clinical benefit through induction of oral tolerance and reduction of immune-mediated liver injury. Once daily dose of V5 was administered per os to 10 patients with chronic hepatitis B in an open label study that lasted one month. Every patient who entered the study had elevated liver enzyme levels, which at the end of study have decreased in 100% of analyzed patients. The reduction was highly significant, from 112.4 to 44.4 U/L (P=0.00009) and 118.8 to 46.1 U/L (P=0.0032), for ALT and AST respectively. In addition, half of intent-to-treat patients who were HBV surface antigen (HBsAg) positive at study entry, became negative after one month on V5 (P=0.0098). All patients, except one, reported complete recuperation from hepatitisassociated clinical symptoms present at baseline (P=0.0016). No adverse events were observed at any time. Favorable biochemical, virological and clinical responses indicate that V5 is safe and effective means for immunotherapy of chronic hepatitis B. Placebo-controlled, randomized study is required to confirm these findings.
Export Options
About this article
Cite this article as:
Batdelger Dendev, Dandii Dorjiin, Jirathitikal Vichai and Bourinbaiar S. Aldar, Open Label Trial of Therapeutic Hepatitis B Vaccine V-5 Immunitor (V5)Delivered by Oral Route, Letters in Drug Design & Discovery 2007; 4 (8) . https://dx.doi.org/10.2174/157018007782794545
DOI https://dx.doi.org/10.2174/157018007782794545 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pathophysiological Role of Pigment Epithelium-Derived Factor (PEDF) in Hepatic Disorders
Current Medicinal Chemistry Ethyl Pyruvate: A Novel Treatment for Sepsis
Current Drug Targets Focus on MicroRNAs as Biomarker in Pediatric Diseases
Current Pharmaceutical Design Antiviral Activity and Molecular Targets of Plant Natural Products Against Avian Influenza Virus
Current Organic Chemistry Molecular Pathways of Interferon-Stimulated Gene 15: Implications in Cancer
Current Protein & Peptide Science Molecular Biological Roles of Ursolic Acid in the Treatment of Human Diseases
Current Bioactive Compounds Anti-Inflammatory Effects of Intravenous Anesthetics on Endotoxemia
Mini-Reviews in Medicinal Chemistry A QSAR Study on Some Thiophene Derivatives Acting as Anti-HCV Agents
Letters in Drug Design & Discovery Pathophysiology of Sepsis in the Elderly: Clinical Impact and Therapeutic Considerations
Current Drug Targets Polycations Selectively Blocking Tissue Factor-Dependent FVII Activation: Collective In Vitro Anticoagulation Studies§
Inflammation & Allergy - Drug Targets (Discontinued) Editorial (Mini-Thematic Issue: Mold Allergens and Antigenic Epitopes Correlation with Fungal Diseases)
Current Protein & Peptide Science Intravenous Immunoglobulin Therapy in Dermatologic Disorders
Inflammation & Allergy - Drug Targets (Discontinued) Clopidogrel and Aspirin in Cardiovascular Medicine: Responders or Not -- Current Best Available Evidence
Cardiovascular & Hematological Agents in Medicinal Chemistry Nanotechnology Applications for Diffuse Intrinsic Pontine Glioma
Current Neuropharmacology Cancer Stem Cells in Hematological Disorders: Current and Possible New Therapeutic Approaches
Current Pharmaceutical Biotechnology Calixarene: A Versatile Material for Drug Design and Applications
Current Pharmaceutical Design Discovery of Thiazole Based Bis Heterocyclic System for Anti- Inflammatory Potential
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Accomplices of NF-κB Lead to Radioresistance
Current Protein & Peptide Science The Metabolic Syndrome and Vascular Disease in Asia
Cardiovascular & Hematological Disorders-Drug Targets Use of Kv1.3 Blockers for Inflammatory Skin Conditions
Current Medicinal Chemistry